Twenty-five-year changing pattern of gonococcal antimicrobial susceptibility in Shanghai: Surveillance and its impact on treatment guidelines

BMC Infectious Diseases

Volumn 14, Issue 1, 2014, Pages

  Gu, Wei Ming ^a   Chen, Yue ^b   Yang, Yang ^a   Wu, Lei ^a   Hu, Wei Zhong ^a   Jin, Yue Lan ^a  

^a Shanghai Skin Disease Hospital   (China)

^b UNIVERSITY OF OTTAWA   (Canada)

Author keywords

Antimicrobial susceptibility; Ceftriaxone; Multiple drug resistance; Neisseria gonorrhoeae; Spectinomycin

Indexed keywords

CEFTRIAXONE; CIPROFLOXACIN; PENICILLIN DERIVATIVE; SPECTINOMYCIN; TETRACYCLINE; ANTIINFECTIVE AGENT;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATE; BACTERIUM ISOLATION; CHINA; CONTROLLED STUDY; FEMALE; HUMAN; MALE; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANCE; NEISSERIA GONORRHOEAE; NONHUMAN; PHENOTYPE; PLASMID; DRUG EFFECTS; GONORRHEA; ISOLATION AND PURIFICATION; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; PHYSIOLOGY; PREVALENCE;

ANTI-BACTERIAL AGENTS; CEFTRIAXONE; CHINA; CIPROFLOXACIN; DRUG RESISTANCE, MULTIPLE, BACTERIAL; GONORRHEA; HUMANS; MICROBIAL SENSITIVITY TESTS; NEISSERIA GONORRHOEAE; PENICILLINS; PREVALENCE; SPECTINOMYCIN; TETRACYCLINE; TETRACYCLINE RESISTANCE;

EID: 84924067149     PISSN: None     EISSN: 14712334     Source Type: Journal    
DOI: 10.1186/s12879-014-0731-9     Document Type: Article

References (39)

1. World Health Organization (WHO): Global incidence and prevalence of selected curable sexually transmitted infections - 2008. 20 Avenue Appia, 1211 Geneva 27, Switzerland: WHO Press, World Health Organization; 2012.
2. Qiu X, Jiang N, Gong X: [Reports on syphilis and gonorrhea in China in 2012]. Bulletin Sex Transm Dis 2013, 266:11-21.
3. Jerse AE, Deal CD: Vaccine research for gonococcal infections: where are we? Sex Transm Infect 2013, 89(Suppl 4):iv63-iv68.
4. Ison CA, Town K, Obi C, Chisholm S, Hughes G, Livermore DM, Lowndes CM: GRASP Collaborative group: Decreased susceptibility to cephalosporins among gonococci: data from the Gonococcal Resistance to Antimicrobials Surveillance Programme (GRASP) in England and Wales, 2007-2011. Lancet Infect Dis 2013, 13:762-768.
5. Ndowa FJ, Ison CA, Cole MJ, Lusti-Narasimhan M: Gonococcal antimicrobial resistance: challenges for public health control. Sex Transm Infect 2013, 89(Suppl 4):iv3-iv4.
6. Unemo M, Shafer WM: Antimicrobial resistance in Neisseria gonorrhoeae in the 21 st century: past, evolution, and future. Clin Microbiol Rev 2014, 27:587-613.
7. Ison CA, Deal C, Unemo M: Current and future treatment options for gonorrhoea. Sex Transm Infect 2013, 89(Suppl 4):iv52-iv56.
8. Unemo M, Nicholas RA: Emergence of multidrug-resistant, extensively drug-resistant and untreatable gonorrhea. Future Microbiol 2012, 7:1401-1422.
9. Allen VG, Mitterni L, Seah C, Rebbapragada A, Martin IE, Lee C, Siebert H, Towns L, Melano RG, Low DE: Neisseria gonorrhoeae treatment failure and susceptibility to cefixime in Toronto, Canada. JAMA 2013, 309:163-170.
10. Lewis DA: Global resistance of Neisseria gonorrhoeae: when theory becomes reality. Curr Opin Infect Dis 2014, 27:62-67.
11. Liao M, Bell K, Gu WM, Yang Y, Eng NF, Fu W, Wu L, Zhang CG, Chen Y, Jolly AM, Dillon JA: Clusters of circulating Neisseria gonorrhoeae strains and association with antimicrobial resistance in Shanghai. J Antimicrob Chemother 2008, 61:478-487.
12. Yang Y, Liao M, Gu WM, Bell K, Wu L, Eng NF, Zhang CG, Chen Y, Jolly AM, Dillon JA: Antimicrobial susceptibility and molecular determinants of quinolone resistance in Neisseria gonorrhoeae isolates from Shanghai. J Antimicrob Chemother 2006, 58:868-872.
13. Ye S, Su X, Wang Q, Yin Y, Dai X, Sun H: Surveillance of antibiotic resistance of Neisseria gonorrhoeae isolates in China, 1993-1998. Sex Transm Dis 2002, 29:242-245.
14. Wang Q, Zhang G: [Guidelines for diagnosis and treatment of sexually transmitted diseases 2007]. Center for Control of Sexually Transmitted Diseases, Center for Disease Control, China (China CDC). Shanghai, China 200235: Shanghai Sciences and Technology Publishing; 2007.
15. Ministry of Health China: [Guidelines for the treatment of sexually transmitted infections 2000]. Nanjing, China: National Center for Leprosy and STD Control; 2000.
16. National Centre for STD Control, China CDC: [Bulletin of Sexually Transmitted Diseases], [Available at: http://www.ncstdc.org/list.asp?id=185; 4 May 2014, date last accessed).
17. Clinical and Laboratory Standard Institute: Performance standards for antimicrobial susceptibility testing: Twenty-fourth informational supplement M100-S24. PA, USA: CLSI Wayne; 2014.
18. European Committee on Antimicrobial Susceptibility Testing (EUCAST): Expert rules 2010 [Available at: http://www.eucast.org/expert_rules. AST to Bacteria Breakpoint Table Version 1.1.; 3 May 2014, date last accessed].
19. Kirkcaldy RD, Kidd S, Weinstock HS, Papp JR, Bolan GA: Trends in antimicrobial resistance in Neisseria gonorrhoeae in the USA: the Gonococcal Isolate Surveillance Project (GISP), January 2006-June 2012. Sex Transm Infect 2013, 89(Suppl 4):iv5-iv10.
20. Martin I, Sawatzky P, Liu G, Allen V, Lefebvre B, Hoang L, Lovgren M, Haldane D, Caeseele PV, Horsman G, Garceau R, Ratnam S, Wong T, Gilmour M: Antimicrobial susceptibilities and distribution of sequence types of Neisseria gonorrhoeae isolates in Canada: 2010. Can J Microbiol 2013, 59:671-678.
21. Lahra MM, Donovan B, Whiley DM: Decreased susceptibility to cephalosporins among gonococci? Lancet Infect Dis 2014, 14:186.
22. Lahra MM: Australian Gonococcal Surveillance Programme: Annual report of the Australian Gonococcal Surveillance Programme, 2011. Commun Dis Intell 2012, 36:E166-E173.
23. Dillon JA, Trecker MA, Thakur SD: Gonococcal Antimicrobial Surveillance Program Network in Latin America and Caribbean 1990-2011: Two decades of the gonococcal antimicrobial surveillance program in South America and the Caribbean: challenges and opportunities. Sex Transm Infect 2013, 89(Suppl 4):iv36-iv41.
24. Su X, Jiang F, Ge Q, Dai X, Sun H, Ye S: Surveillance of antibmicrobial susceptibilitites in Neisseria gonorrhoeae in Nanjing, China, 1999-2006. Sex Transm Dis 2007, 34:995-999.
25. Chen SC, Yin YP, Dai XQ, Unemo M, Chen XS: Antimicrobial resistance, genetic resistance determinants for ceftriaxone and molecular epidemiology of Neisseria gonorrhoeae isolates in Nanjing, China. J Antimicrob Chemother 2014, 69:2959-2965.
26. Zhu BY, Yu RX, Yin Y, Chen X, Li W, Dai XQ, Liang M, Gan Q, Huang YJ, Wei JP: Surveillance of antimicrobial susceptibilities of Neisseria gonorrhoeae in Nanning, China, 2000-2012. Sex Transm Dis 2014, 41:501-506.
27. Thakur SD, Starnino S, Horsman GB, Levett PN, Dillon JR: Unique combined penA/mtrR/porB mutations and NG-MAST strain types associated with ceftriaxone and cefixime MIC increases in a 'susceptible' Neisseria gonorrhoeae population. J Antimicrob Chemother 2014, 69:1510-1516.
28. Martin I, Jayaraman G, Wong T, Liu G, Gilmour M: Canadian Public Health Laboratory Network: Trends in antimicrobial resistance in Neisseria gonorrhoeae isolated in Canada: 2000-2009. Sex Transm Dis 2011, 38:892-898.
29. Hottes TS, Lester RT, Hoang LM, McKay R, Imperial M, Gilbert M, Patrick D, Wong T, Martin I, Ogilvie G: Cephalosporin and azithromycin susceptibility in Neisseria gonorrhoeae isolates by site of infection, British Columbia, 2006 to 2011. Sex Transm Dis 2013, 40:46-51.
30. Public Health Agency of Canada: Canadian Guidelines on Sexually Transmitted Infections, 2008 Edition. Public Health Agency of Canada. Ottawa, ON, Canada; 2008.
31. Bignell C, Fitzgerald M: UK national guideline for the management of gonorrhea in adults, 2011. Int J STD AIDS 2011, 22:541-547.
32. Sexual Health Society of Victoria: National Management Guidelines for Sexually Transmitted Infections 7th edition. Melbourne, Australia: Sexual Health Society of Victoria; 2008.
33. Centers for Disease Control and Prevention: Update to CDC's Sexually transmitted diseases treatment guidelines, 2010: oral cephalosporins no longer a recommended treatment for gonococcal infections. Morb Mortal Wkly Rep 2012, 61:590-594.
34. Centers for Disease Control and Prevention: Sexually transmited disease treatment guidelines, 2010. Morb Mortal Wkly Rep 2010, 59(RR12):50-52.
35. World Health Organization: Antimicrobial resistance in Neisseria gonorrhoeae. Available at WHO/CDS/CSR/DRS/2001.3. 2001. (3 May 2014, date last accessed). http://www.who.int/drugresistance/Antimicrobial_resistance:in_Neisseria_gonorrhoeae.pdf
36. Pereira R, Cole MJ, Ison CA: Combination therapy for gonorrhoea: in vitro synergy testing. J Antimicrob Chemother 2013, 68:640-643.
37. Lusti-Narasimhan M, Pessoa-Silva CL, Temmerman M: Moving forward in tackling antimicrobial resistance: WHO actions. Sex Transm Infect 2013, 89(Suppl 4):iv57-iv59.
38. Ndowa F, Lusti-Narasimhan M, Unemo M: The serious threat of multidrug-resistant and untreatable gonorrhoea: the pressing need for global action to control the spread of antimicrobial resistance, and mitigate the impact on sexual and reproductive health. Sex Transm Infect 2012, 88:317-318.
39. Gil-Setas A, Navascués-Ortega A, Beristain X: Spectinomycin in the treatment of gonorrhoea. Euro Surveill, 2010; 15:pii = 19568. Available at http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=19568. (3 May 2014, date last accessed).